Literature DB >> 27907876

Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.

Ewa Surmiak1, Constantinos G Neochoritis2, Bogdan Musielak1, Aleksandra Twarda-Clapa3, Katarzyna Kurpiewska1, Grzegorz Dubin3, Carlos Camacho4, Tad A Holak5, Alexander Dömling6.   

Abstract

Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Potent compounds evolved inhibiting the protein-protein interaction p53-MDM2. An extensive SAR study was performed based on our four-point pharmacophore model, yielding derivatives with affinity to MDM2 in the nanomolar range. Their binding affinity with MDM2 was evaluated using both fluorescence polarization (FP) assay and 2D-NMR-HSQC experiments.
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27907876     DOI: 10.1016/j.ejmech.2016.11.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  11 in total

1.  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

Authors:  Constantinos G Neochoritis; Jack Atmaj; Aleksandra Twarda-Clapa; Ewa Surmiak; Lukasz Skalniak; Lisa-Maria Köhler; Damian Muszak; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Barbara Beck; Tad A Holak; Alexander Dömling
Journal:  Eur J Med Chem       Date:  2019-08-06       Impact factor: 6.514

2.  A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Authors:  Lukasz Skalniak; Aleksandra Twarda-Clapa; Constantinos G Neochoritis; Ewa Surmiak; Monika Machula; Aneta Wisniewska; Beata Labuzek; Ameena M Ali; Sylwia Krzanik; Grzegorz Dubin; Matthew Groves; Alexander Dömling; Tad A Holak
Journal:  FEBS J       Date:  2019-02-16       Impact factor: 5.542

Review 3.  In silico structure-based approaches to discover protein-protein interaction-targeting drugs.

Authors:  Woong-Hee Shin; Charles W Christoffer; Daisuke Kihara
Journal:  Methods       Date:  2017-08-09       Impact factor: 3.608

4.  AnchorQuery: Rapid online virtual screening for small-molecule protein-protein interaction inhibitors.

Authors:  David R Koes; Alexander Dömling; Carlos J Camacho
Journal:  Protein Sci       Date:  2017-10-24       Impact factor: 6.725

5.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

Review 6.  Tetrazoles via Multicomponent Reactions.

Authors:  Constantinos G Neochoritis; Ting Zhao; Alexander Dömling
Journal:  Chem Rev       Date:  2019-02-01       Impact factor: 60.622

7.  Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.

Authors:  Constantinos G Neochoritis; Maryam Kazemi Miraki; Eman M M Abdelraheem; Ewa Surmiak; Tryfon Zarganes-Tzitzikas; Beata Łabuzek; Tad A Holak; Alexander Dömling
Journal:  Beilstein J Org Chem       Date:  2019-02-20       Impact factor: 2.883

8.  Artificial Macrocycles as Potent p53-MDM2 Inhibitors.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Aleksandra Twarda-Clapa; Bogdan Musielak; Tad A Holak; Alexander Dömling
Journal:  ACS Med Chem Lett       Date:  2017-09-20       Impact factor: 4.345

9.  Combining the Ugi-azide multicomponent reaction and rhodium(III)-catalyzed annulation for the synthesis of tetrazole-isoquinolone/pyridone hybrids.

Authors:  Gerardo M Ojeda; Prabhat Ranjan; Pavel Fedoseev; Lisandra Amable; Upendra K Sharma; Daniel G Rivera; Erik V Van der Eycken
Journal:  Beilstein J Org Chem       Date:  2019-10-16       Impact factor: 2.883

10.  Rapid Discovery of Aspartyl Protease Inhibitors Using an Anchoring Approach.

Authors:  Markella Konstantinidou; Francesca Magari; Fandi Sutanto; Jörg Haupenthal; Varsha R Jumde; M Yagiz Ünver; Andreas Heine; Carlos Jamie Camacho; Anna K H Hirsch; Gerhard Klebe; Alexander Dömling
Journal:  ChemMedChem       Date:  2020-03-18       Impact factor: 3.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.